
---
title: '恒瑞医药：HR20014注射液获得药物临床试验批准通知书'
categories: 
 - 金融
 - 证券时报网
 - 快讯
headimg: 'https://picsum.photos/400/300?random=6981'
author: 证券时报网
comments: false
date: Tue, 09 Aug 2022 15:59:00 GMT
thumbnail: 'https://picsum.photos/400/300?random=6981'
---

<div>   
<p>证券时报e公司讯，<a class="trsHotWords" href="https://info.stcn.com/dc/stock/?stockcode=SS600276" style="color: #2f67d1;text-decoration: none;" code="600276" target="_blank">恒瑞医药</a>(600276)8月9日晚间公告，近日，公司收到国家药监局核准签发关于HR20014注射液的《药物临床试验批准通知书》，将于近期开展临床试验。HR20014 注射液临床拟用于治疗糖尿病。</p>

                  
</div>
            